Q32 Bio Inc. (NASDAQ:QTTB) Holdings Increased by Barclays PLC

Barclays PLC lifted its stake in Q32 Bio Inc. (NASDAQ:QTTB) by 105.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,443 shares of the company’s stock after acquiring an additional 5,353 shares during the period. Barclays PLC owned 0.09% of Q32 Bio worth $465,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Jane Street Group LLC acquired a new stake in Q32 Bio in the third quarter worth approximately $733,000. State Street Corp raised its stake in shares of Q32 Bio by 35.5% in the 3rd quarter. State Street Corp now owns 110,164 shares of the company’s stock worth $4,916,000 after buying an additional 28,865 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Q32 Bio in the third quarter valued at $3,422,000. Eventide Asset Management LLC bought a new position in Q32 Bio during the third quarter valued at about $8,478,000. Finally, MetLife Investment Management LLC acquired a new position in Q32 Bio during the third quarter worth about $159,000. 31.32% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

QTTB has been the subject of a number of research analyst reports. Leerink Partnrs downgraded shares of Q32 Bio from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 11th. Leerink Partners reissued a “market perform” rating and set a $9.00 target price (down from $68.00) on shares of Q32 Bio in a research note on Wednesday, December 11th. BMO Capital Markets decreased their price target on shares of Q32 Bio from $64.00 to $22.00 and set an “outperform” rating on the stock in a research report on Thursday, December 12th. Guggenheim downgraded Q32 Bio from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 11th. Finally, Raymond James reissued an “outperform” rating and set a $22.00 price objective (down from $90.00) on shares of Q32 Bio in a research note on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Q32 Bio presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.86.

Q32 Bio Price Performance

Shares of NASDAQ:QTTB opened at $3.45 on Friday. The company’s fifty day moving average is $25.33 and its two-hundred day moving average is $32.40. The company has a market cap of $42.02 million, a P/E ratio of -0.24 and a beta of -0.46. Q32 Bio Inc. has a 12-month low of $3.02 and a 12-month high of $53.79. The company has a quick ratio of 6.53, a current ratio of 6.53 and a debt-to-equity ratio of 0.61.

Q32 Bio Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.